- Home
- SISI vs BIAF Comparison
SISI vs BIAF Comparison
Compare SISI & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- BIAF
- Stock Information
- Founded
- SISI 1997
- BIAF 2014
- Country
- SISI China
- BIAF United States
- Employees
- SISI N/A
- BIAF N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SISI Health Care
- BIAF Health Care
- Exchange
- SISI Nasdaq
- BIAF Nasdaq
- Market Cap
- SISI 14.9M
- BIAF 12.2M
- IPO Year
- SISI 2016
- BIAF 2022
- Fundamental
- Price
- SISI $0.21
- BIAF $0.30
- Analyst Decision
- SISI
- BIAF Hold
- Analyst Count
- SISI 0
- BIAF 1
- Target Price
- SISI N/A
- BIAF N/A
- AVG Volume (30 Days)
- SISI 5.5M
- BIAF 11.2M
- Earning Date
- SISI 05-15-2025
- BIAF 08-13-2025
- Dividend Yield
- SISI N/A
- BIAF N/A
- EPS Growth
- SISI N/A
- BIAF N/A
- EPS
- SISI N/A
- BIAF N/A
- Revenue
- SISI $9,601,324.00
- BIAF $8,809,228.00
- Revenue This Year
- SISI N/A
- BIAF N/A
- Revenue Next Year
- SISI N/A
- BIAF $20.00
- P/E Ratio
- SISI N/A
- BIAF N/A
- Revenue Growth
- SISI 1133.26
- BIAF 78.40
- 52 Week Low
- SISI $0.18
- BIAF $0.16
- 52 Week High
- SISI $117.65
- BIAF $2.99
- Technical
- Relative Strength Index (RSI)
- SISI 29.00
- BIAF 50.96
- Support Level
- SISI $0.18
- BIAF $0.22
- Resistance Level
- SISI $0.34
- BIAF $0.46
- Average True Range (ATR)
- SISI 0.05
- BIAF 0.04
- MACD
- SISI -0.01
- BIAF 0.01
- Stochastic Oscillator
- SISI 11.25
- BIAF 30.51
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.